Online inquiry

IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15486MR)

This product GTTS-WQ15486MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15486MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9505MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ5165MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ922MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ6898MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ2964MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ2071MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ2157MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ703MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA A-1230717
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW